Advanced Viral Research's CEO Shalom Hirschman talks to The Wall Street Transcript.Business Editors NEW YORK--(BUSINESS WIRE)--Aug. 14, 2000 The Wall Street Transcript has published an in-depth interview with Shalom Hirschman, MD, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Advanced Viral Research Corporation (OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). BB:ADVR ADVR Association of Directors of Volunteer Resources (Canada) .OB), in which he talks at length about the company's future. The entire 1,300-word interview is available free online at http://www.twst.com/ceos.htm Hirschman gives an overview of the company. "Advanced Viral Research Corp. is a biopharmaceutical company that is developing a new type of a non-toxic immunomodulator drug for the treatment of both viral diseases viral diseases Diseases caused by viruses. Long-term immunity usually follows viral childhood diseases (see chickenpox). The common cold recurs into adulthood because many different viruses cause its symptoms, and immunity against one does not protect against others. , such as AIDS, and autoimmune diseases Autoimmune diseases A group of diseases, like rheumatoid arthritis and systemic lupus erythematosus, in which immune cells turn on the body, attacking various tissues and organs. Mentioned in: Complement Deficiencies, Premature Menopause , such as rheumatoid arthritis rheumatoid arthritis Chronic, progressive autoimmune disease causing connective-tissue inflammation, mostly in synovial joints. It can occur at any age, is more common in women, and has an unpredictable course. ." Hirschman explains, "Our objective is to bring our Product R to market as quickly as possible because there is a great need for this new type of therapy. We already have a long pipeline, but at the beginning we are targeting several major diseases. Where we are in fact most advanced is in having both the basic scientific data and clinical data. Those are, first, infection with the human immunodeficiency virus human immunodeficiency virus n. HIV. Human immunodeficiency virus (HIV) A transmissible retrovirus that causes AIDS in humans. , that is, the treatment of AIDS, where it is my objective to make this immunomodulator one of the anchor drugs for the treatment of all patients with AIDS. There are tremendous advantages to using this type of immunomodulator in combination with the drug that directly affects viral replication, which are the standard cocktail drugs used now." Looking forward, Hirschman states, "We have designed different conjurners of this drug, meaning new generations of drugs based on this chemistry. It's a very rich chemistry, and it's a very exciting chemistry. Given the great need for this type of drug, I hope that we will be able to reach the marketplace by sometime in the year 2001." This interview is part of a 114-page Global Healthcare Investments in Biotechnology and Pharmaceuticals Issue available at http://www.twst.com/info/info152.htm or by calling 212/952-7433 The Wall Street Transcript is a premier weekly investment publication serving serious long-term investors for over 37 years. The Wall Street Transcript has launched a new free service where investors can ask Advanced Viral Research (or any public company) a question at http://www.qawire.com The Wall Street Transcript does not endorse the views of any interviewees nor does it make stock recommendations. For subscription information call 800/246-7673. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion